Irodalom
1. Andreone P, Cursaro C, Gramenzini A, et al.: Interferon alpha plus ketoprofen or interferon
alpha plus ribavirin in chronic hepatitis C non-responder to interferon alpha alone: results of a
pilot study. Ital J. Gastroenterol Hepatol. 1999; 31: 688-694.
2. Andrikovics H, Klein I, Kalmár L, és mtsai: Új molekularis genetikai módszer az öröklődő
haemochromatosis differenciáldiagnosztikájában. Orv. Hetil. 1999; 140: 2517-2522.
3. Angulo P. et al.: Time course of histological progression in primary sclerosing cholangitis.
Amer. J. Gastroenterol. 1999: 94: 3310-3313.
4. Bass NM.: Intravenous albumin for spontaneous bacterial peritonitis in patients with cirrhosis.
New. Engl. J.Med. 1999: 341: 443-444.
5. Bellobuono A, Mondazzi L, Tempini S. et al: Should patients with early loss of serum
HCV-RNA during alpha interferon therapy for chronic hepatitis C be treated for 6 or 12 months?
J. Hepatology, 1999; 30: 8-13.
6. Beuers U., et al.: Therapie der autoimmunen Hepatitis, primar biliaren Zirrhose und primar
sklerosierenden Cholangitis. (Konsensus der Deutschen Gesellschaft für Vedaung- und
Stoffwechselkrankheiten). Z. Gastroenterol. 1999: 35: 1041-1049.
7. Blendis L., Wong F.: Does repeted paracentesis prevent spontaneous bacterial peritonitis?
Amer. J. Gastroenterol. 1999: 94: 2798-2800.
8. Bonkovsky HL, et al.: Hepatic iron concentration: non-invasive estimation by means of MR
imaging techniques. Radiology 1999: 212: 212-234.
9. Brouwer JT, Hansen BE, Niesters HGM et al: Early prediction of response in interferon
monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA
at 4 weeks versus ALT. J. Hepatology 1999; 30: 192-198.
10. Cohen J: The scientific challange of hepatitis C. Science 1999; 285: 26-30.
11. Cucuianu A, Patiu M, Duma M, et al.: Hepatitis B and C virus infection in Romanian
non-Hodgkin’s lymphoma patients. Brit J Haematology 1999; 107: 353- 356.
12. Daniel S. et.al.: Prospective evaluation of unexplained chronic liver transaminase
abnormalities in asymptomatic and symptomatic patients. Amer.J. Gastroenterol. 1999: 94:
3010-3015.
13. Delpre G., Niv Y.: Sherlock Holmes magnifying glass to identify Wilsons disease. Amer.J.
Gastroenterol. 1999: 117: 2635.
14. Deschenes M. et al.: Risk factors for the development of bacterial infections in hospitalized
patients with cirrhosis. Amer. J. Gastroenterol. 1999: 94: 2193-2197.
15. Devereauw CE. Et al.: Ascites and severe hepatitis complicating Epstein-Barr infection.
Amer. J. Gastroenterol. 1999: 94: 236-240.
16. EASL: Consensus Conference of Hepatitis C virus. J. Hepatology, 1999; 31. suppl. 1.
17. Farkas H. et al.: Acquired angioedema associated with chronic hepatitis-C. J. Allergy Clic.
Immunol. 1999: 4: 711-712.
18. Farkas H. et al.: An uncommon disorder with ascites. Annual Meeting of the Hungarian
Society of Gastroenterol. Abstracts, 1999: 53.
19. Fehér J, Lengyel G, Bálint T és mtsai: Interfenon alpha-2b és ribavirin kombinált kezelés
krónikus C hepatitisben. 100 beteg egy évig tartó kezelése során szerzett tapasztalatok. Orv.
Hetil. 1999; 140: 1235-1238.
20. Giménez-Barcons M, Forns X, Ampurdanes S et al: Infection with a novel human DNA
virus (TTV) has no pathogenic significance in patients with liver diseases. J. Hepatology 1999;
30: 1028-1034.
21. Gronbaek K, Krarup HB, Moller H et al. Natural history and etiology of liver disease in
patients with previous community-acquired acute non-A, non-B hepatitis. J. Hepatology 1999;
193
31: 800-807.
22. Heathcote EJL, James S, Mullen KD et al: Chronic hepatitis C virus patients with
breakthroughs during interferon treatment can successfully be retreated with consensus
interferon. Hepatology 1999; 30: 562-566.
23. Ikeda H, Takasu M, Inoue K et al: Infection with an unenveloped DNA virus (TTV) in
patients with acute or chronic liver disease of unknown etiology and in those positive for
hepatitis C virus RNA. J. Hepatol 1999; 30: 205-21.
24. Imperial TF. et al: Corticosteroids are effective in patients with severe alcoholic hepatitis,
1999: 94: 3066-3067.
25. James OFW. et al.: Primary biliary cirrhosis once rare, now common in the UK? Hepatology
1999: 30: 390-394.
26. Jeffries MA., et al.: Unsuspected infection is infrequent in asymptomatic outpatients with
refractory ascites undergoing therapeutic paracentesis. Amer. J. Gastroenterol. 1999: 94:
2972-2976.
27. Johnson MA, Moore KHP, Yuen GJ et al. Clinical pharmacokinetics of lamivudine. Clin.
Pharmacokinet. 1999; 36: 41-66.
28. Kanzler S, Weidemann C, Gerken G et al Clinical significance of autoantibodies to soluble
liver antigen in autoimmune hepatitis. J. Hepatology, 1999; 31: 635-640.
29. Kaplan MM. Et al.: A prospective trial of colchicine and methotrexate in the treatment of
primary biliary cirrhosis. Gastroenterology 1999: 117: 1173-1180.
30. Kowdley KV.: Clinical issues in haemochromatosis and liver disease. Gastroenterology
1999, 116: 201.
31. Leuschner M. et al.: Oral budenoside and ursodeoxycholic acid for treatment of primary
biliary cirrhosis. Gastroenterology, 1999: 117: 918-925.
32. Locarnini S, Birch A. Antiviral chemotherapy for chronic hepatitis B: lessons learned from
treating HIV infected patients. J. Hepatology 1999; 30: 536-550.
33. Lohmann, V, Körner F, Koch J-O et al. Replication of subgenomic hepatitis C virus RNAs
in a hepatoma cell line. Science 1999; 285. 110-113.
34. Macdonald G.A., Powell LW.: More clues to the relationship between hepatic iron and
steatosis: an association with insuline resistance Gastroenterology 1999: 117: 1241-1243.
35. Macedo G. et al.: Cirrhosis and diabetes. Amer-J. Gastroenterology 1999: 94-: 3088-3089.
36. Martins E. et al.: Sclerosing cholangitis. Opin. Gastroenterol. 1999: 15: 436-441.
37. Mendler HM et al.: Insuline resitance-associated iron overload. Gastroenterology 1999: 117:
1155-1163.
38. Nakano T, Park Y-M, Mizokami M et al TT virus infection among blood donors and patients
with non-B, non-C liver dieases in Korea. J. Hepatology 1999; 30: 389-393.
39. Nemesánszky E.: Alkoholos májbetegségek diagnosztikája. Folia Hematológia 1999: 4:
19-25.
40. Neuberger J., James O.: Guidelines for selection of patients for liver transplantation in the
era of donor-organ shortage. Lancet 1999: 354: 1636-1639.
41. Niederau C, Erhardt A, Haussinger D et al: Haemochromatosis and the liver. J. Hepatology
1999; 30: 6-11.
42. Olynyk JK: Hereditary haemochromatosis: diagnosis and management in the gene era. Liver
1999; 19: 73-80.
43. Pár A, Telegdy L, Gógl Á és mtsai: Krónikus virushepatitisek interferon kezelése
Magyarországon: 5 éves tapasztalatok. Multicentrikus tanulmány. Orv. Hetil. 1999; 140:
1227-1233.
44. Pár A.: Az alkoholos májbetegségek terápiája: Folia Haepatológia. 1999: 4: 25-32.
45. Perrillo R, Rakela J, Dienstag J et al: Multicenter study of Lamivudine therapy for hepatitis
194
B after liver transplantation.. Hepatology 1999; 29: 1581-1586.
46. Pol ST, Couzigou P, Bourliere M et al: A randomized trial of ribavirin and inteferon-alpha
vs. interferon-alpha alone in patients wit chronic hepatitits C who were non-responders to a
previous treatment. J. Hepatology, 1999; 31: 1-7.
47. Poynard T, Naveau S, Doffel M et al Evaluation of efficacy of liver transplantation in
alcoholic cirrhosis using matched and simulated controls: 5 year survival. J.Hepatology 1999;
30: 1130-1137.
48. Pozzato G, Burrone O, Baba K, et al: Ethnic difference in the prevalence of monoclonal B
cell proliferation in patients affected by hepatitits C virus chronic liver disease. J. Hepatology
1999; 30: 990-994.
49. Pusztay M., Nemesánszky E.: Interferonkezelés hatása a hepatitis-C virus indukálta krónikus
májbetegek szénhidrát-metabolizmusára. Orvosi Hetil. 1999: 140: 1579-1581.
50. Ratziu V, Samuel D, Sebgh M et al: Long-term follow-up after liver transplantation for
autoimmune hepatitis: evidence of recurrence of primary disease. J. Hepatology, 1999; 30:
131-141.
51. Runyon BR.: Albumin infusion for spontaneous bacterial peritonitis. Lancet, 1999: 354:
1838-1839.
52. Smolarek C., Stremmel W.: Therapie des Morbus Wilson. Z.Gastroenterol. 1999: 37:
293-300.
53. Swift RM.: Drug therapy for alcohol dependence. New.Engl. J.Med. 1999: 340: 1482-1490.
54. Taylor DR, Shi ST, Romano PR et al Inhibition of the interferon-inducible protein kinase
PKR by HCV E2 protein. Science 1999; 285: 107-110.
55. Vila CM. Et al.: Total paracentesis in cirrhotic patients with tense ascites and dilutional
hyponatremia. Amer. J. Gastroenterol. 1999: 94: 2219-2223.
56. Zignego AL, Brechot C.Extrahepatic manifestations of HCV infection: facts and
controversies. Review. J. Hepatology 1999; 31: 369-376.
